Ozempic is suspected in more cases of sudden vision loss Scientists remain puzzled as to why some people taking popular weight loss and diabetes medications like Ozempic and Wegovy are losing their vision suddenly, highlighting that there's still so much we don't know about this life-changing cl...
Home»Accurate Education – GLP-1 Receptor Agonists “Let your food be your medicine, and your medicine be your food.”— Hippocrates Weight Loss: GLP-1 Receptor Agonists: Semaglutide(Ozempic, Wegovy, Rybelsus) Liraglutide(Saxenda) Dulaglutide(Trulicity) ...
Both glucagon-like peptide-1 receptor agonists (GLP-1RA) and sodium-glucose cotransporter-2 (SGLT-2) inhibitors can reduce CV risk in patients with T2D, and both are recommended by the American Diabetes Association to reduce the risk of major cardiovascular events (MACE). The magnitude of the...
Glucagon-like peptide-1 (GLP-1) receptor agonists are popular medications used to treat Type 2 diabetes. Some are also approved for weight loss. Ozempic (semaglutide) and Victoza (liraglutide) are examples that treat Type 2 diabetes. Wegovy and Saxenda are higher-dose versions of each medication...
cardiovascular outcomes (MACE; A), cardiovascular death (B), non-fatal stroke (C), non-fatal myocardial infarction (D), and hospitalization for heart failure (E) reported from cardiovascular outcome studies with GLP-1 receptor agonists (red), SGLT-2 inhibitors (blue), and DPP-4 inhibitors (...
Previous studies have explored the effects of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in reducing cardiovascular events in type 2 diabetes. Here we show that GLP-1 RAs are associated with lower risks of mortality, major cardiovascular events (MACEs), and major adverse kidney event...
GLP-1 receptor agonists is an efficacious therapeutic option for the treatment of type 2 diabetes. These work by stimulating the beta cells of the pancreas to release more insulin when blood sugar levels are high. This unique mechanism of action enables better glycemic control along with weight ...
GLP-1 receptor agonists are approved for the treatment of type 2 diabetes, and more recently for obesity treatment. The glucagon-like-peptide-1 (GLP-1) is a glucose dependent hormone produced by intestinal cells, which is involved in insulin secretion and glucagon suppression. This hormone ...
found GLP1RAs not linked to increased risk of thyroid cancer over mean follow-up of 3.9 years (occurred in 76 on GLP-1 receptor agonists and 184 on DPP-4 inhibitors; incidence rate 1.33 vs 1.46 events/10,000 person-years, respectively, HR 0.93, 95% CI 0.66-1.31) ...
本研究针对GLP-1受体激动剂(GLP-1 RAs)的神经安全性问题,通过分析FDA不良事件报告系统(FAERS)2005-2024年数据,首次系统识别出19种神经不良事件(NAEs)信号,包括味觉障碍(ROR=2.55)和异常性疼痛(ROR=25.55),中位发生时间为32天。研究为糖尿病和肥胖患者的用药安全监测提供了重要循证依据。